Determination of serum bone-related minerals during denosumab treatment in osteoporosis patients with rheumatoid arthritis

Denosumab might be a good option to improve bone-related minerals in OP patients with RA even without dietary supplement. Serum Fe and Mg values became approximately within normal range after the therapy. On the other hand, serum Zn significantly increased for 12 months, however, the Zn values showed still low status after the treatment. Thus, Zn supplementation and/or nutrition education are basically required for OP patients with RA, even though denosumab increases serum Zn level.